Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Status of the clinical evaluation of levodopa in the treatment of Parkinson's disease and syndrome

Status of the clinical evaluation of levodopa in the treatment of Parkinson's disease and syndrome The effect of levodopa on Parkiruon's disease and syndrome was studied in a total of 1,533 patients according to a protocol for open clinical evaluation. The average daily dose to achieve maximum relief of clinical symptoms with tolerable side effects ranged from between 3.5 and 6.5 Gm. per day given in divided doses. The dosage of levodopa, sometimes administered concomitantly with other antiparkinson agents, was increased slowly in small increments, and dosage regimens were individualized for each patient according to his response. Approximately two thirds of the patients treated achieved a satisfactory resporue, while side effects occurred in over 90 per cent of the patients treated. Improvement in clinical symptomatology was sometimes delayed but continued on long‐term maintenance therapy. Laboratory abnormalities, though frequent, were rarely serious and, to date, are reversible. An additional 3,000 patients were monitored for severe and unusual reactioru and deaths. No death in any of the studies was attributed directly to the administration of the drug; however, experience showed that psychiatric changes masked by Parkinson's disease may manifest themselves in depression with suicidal tendencies as therapeutic doses are approached. It is concluded that, with proper care and careful management, levodopa appears to be a relatively safe and effective agent for the treatment of Parkinson's disease and syndrome. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Pharmacology & Therapeutics Wiley

Status of the clinical evaluation of levodopa in the treatment of Parkinson's disease and syndrome

Download PDF
9 pages

Loading next page...
 
/lp/wiley/status-of-the-clinical-evaluation-of-levodopa-in-the-treatment-of-rsdLxRJsLx

References (10)

Publisher
Wiley
Copyright
© American Society for Clinical Pharmacology and Therapeutic
ISSN
0009-9236
eISSN
1532-6535
DOI
10.1002/cpt1971122part2323
Publisher site
See Article on Publisher Site

Abstract

The effect of levodopa on Parkiruon's disease and syndrome was studied in a total of 1,533 patients according to a protocol for open clinical evaluation. The average daily dose to achieve maximum relief of clinical symptoms with tolerable side effects ranged from between 3.5 and 6.5 Gm. per day given in divided doses. The dosage of levodopa, sometimes administered concomitantly with other antiparkinson agents, was increased slowly in small increments, and dosage regimens were individualized for each patient according to his response. Approximately two thirds of the patients treated achieved a satisfactory resporue, while side effects occurred in over 90 per cent of the patients treated. Improvement in clinical symptomatology was sometimes delayed but continued on long‐term maintenance therapy. Laboratory abnormalities, though frequent, were rarely serious and, to date, are reversible. An additional 3,000 patients were monitored for severe and unusual reactioru and deaths. No death in any of the studies was attributed directly to the administration of the drug; however, experience showed that psychiatric changes masked by Parkinson's disease may manifest themselves in depression with suicidal tendencies as therapeutic doses are approached. It is concluded that, with proper care and careful management, levodopa appears to be a relatively safe and effective agent for the treatment of Parkinson's disease and syndrome.

Journal

Clinical Pharmacology & Therapeutics – Wiley

Published: Mar 1, 1971

There are no references for this article.